Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Seizures × enzalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 64 Prostatic Neoplasms, Castration-Resistant 13 Neoplasms 13 Neoplasm Metastasis 9 Breast Neoplasms 8 Metastatic Castration Resistant Prostate Cancer 7 Prostate Cancer Metastatic 5 Metastatic Castration-Resistant Prostate Cancer 5 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Metastatic Castration-resistant Prostate Cancer 3 Melanoma 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 mCRPC 2 Recurrence 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Bulbo-Spinal Atrophy, X-Linked 2 Bites and Stings 2 Uterine Cervical Neoplasms 1 Seizures 1 Prostate Adenocarcinoma 1 Pharmacokinetics of MDV3100 1 Pancreatic Neoplasms 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasms, Squamous Cell 1 Neoplasms by Site 1

Interventions

Cannabidiol 3 enzalutamide 1 Solutions 1 Lenalidomide 1 Everolimus 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01977651 2024-12-06

UPWARD

Astellas Pharma Inc

Phase 4 Completed

424 enrolled 10 charts

Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡